- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 151623 |
Applications | IHC WB |
Antigen/Gene or Protein Targets | Integrin avß6 |
Reactivity | Human |
Relevance | Alpha-v beta-6 is upregulated on cancers and during tissue remodelling but is weak absent on resting adult tissues. It promotes invasion and correlates with poor survival. It is likely to be good therapeutic target. |
Host | Rat |
Immunogen | Mouse fibroblasts retrovirally infected with cDNA to human beta6 (3T3β6.19). Cells expressed a mouse/human avβ6 chimera. |
Positive Control | BT20 breast carcinoma, original immunogen. |
Subclass | IgG1 |
Recommended Growing Conditions | DMEM containing glucose(4.5g/litre), bicarbonate(3.7g/litre), glutamine (4 x 10-3 M), penicillin(50U/ml), streptomycin(50ug/ml)and neomycin(100ug/ml). Also straight DMEM or RPMI 1640 with 3% FCS. |
Notes | Does not recognise mouse avβ6 |
Research Area | Cell Structure and Motility |
References: 2 entries
Marsh et al. 2008. Cancer Res. 68(9):3295-303. PMID: 18451156.
alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
Europe PMC ID: 18451156
Add a reference
References: 2 entries
Marsh et al. 2008. Cancer Res. 68(9):3295-303. PMID: 18451156.
alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
Add a reference